Status:
COMPLETED
Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Sanofi
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The main purpose of the study is to compare the mean AERP between treatment groups based on the hypothesis that in subjects with paroxysmal AF, Irbesartan prevents electrophysiological remodeling resu...
Eligibility Criteria
Inclusion
- Recurrent PAF with indication for catheter ablation
Exclusion
- Struct. Cardiopathy
- Mitral valve disease
- VEF\<40%
- Myocardiopathy
- LVH
- cardiac surgery
- AF reversible
- QT c\>450
- Recent MI/stroke, severe HTN
- Requirement of ACEI/ARBs
- Coronary synd., HTA, liver disease
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00352560
Start Date
July 1 2006
End Date
June 1 2007
Last Update
February 17 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Madrid, Spain, 28040
2
Local Institution
Madrid, Spain, 28046
3
Local Institution
Madrid, Spain, 28905